Y420 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±Û·çÄÚÄÝƼÄÚÀÌµå ¹× ÇÕ¼º´ëÄ¡¹° | Glucocorticoids and synthetic analogues causing adverse effects in therapeutic use |
|
Y421 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â °©»ó¼± È£¸£¸ó ¹× ´ëÄ¡¹° | Thyroid hormones and substitutes causing adverse effects in therapeutic use |
|
Y422 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Ç×°©»ó¼±Á¦ | Antithyroid drugs causing adverse effects in therapeutic use |
|
Y423 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Àν¶¸° ¹× °æ±¸ÀúÇ÷´ç[Ç×´ç´¢º´]Á¦ | Insulin and oral hypoglycemic [antidiabetic] drugs causing adverse effects in therapeutic use |
|
Y424 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â °æ±¸ÇÇÀÓÁ¦ | Oral contraceptives causing adverse effects in therapeutic use |
|
Y424 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ´Ù¼ººÐ ¹× ´ÜÀϼººÐ Á¦Á¦ | Multiple-and single-ingredient preparations causing adverse effects in therapeutic use |
|
Y425 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±âŸ ¿¡½ºÆ®·Î°Õ ¹× ÇÁ·Î°Ô½ºÅ×·Ð | Other estrogens and progestogens causing adverse effects in therapeutic use |
|
Y425 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â È¥ÇÕ¹° ¹× ´ëÄ¡¹° | Mixtures and substitutes causing adverse effects in therapeutic use |
|
Y426 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ´Þ¸® ºÐ·ùµÇÁö ¾ÊÀº Ç×°í³ªµµÆ®·ÎÇÉÁ¦, Ç׿¡½ºÆ®·ÎÁ¨Á¦, Ç׾ȵå·ÎÁ¨Á¦ | Antigonadotrophins, antiestrogens, antiandrogens, NEC causing adverse effects in therapeutic use |
|
Y426 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Ÿ¸ñ½ÃÆæ | Tamoxifen causing adverse effects in therapeutic use |
|
Y427 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ¾Èµå·ÎÁ¨ ¹× ÇÕ¼º´ë»ç µ¿Á¾Ã¼ | Androgens and anabolic congeners causing adverse effects in therapeutic use |
|
Y428 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±âŸ ¹× »ó¼¼ºÒ¸íÀÇ È£¸£¸ó ¹× ÇÕ¼º ´ëÄ¡¹° | Other and unspecified hormones and their synthetic substitutes causing adverse effects in therapeutic use |
|
Y428 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ³úÇϼöü Àü¿± È£¸£¸ó | Anterior pituitary [adenohypophyseal] hormons causing adverse effects in therapeutic use |
|
Y429 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±âŸ ¹× »ó¼¼ºÒ¸íÀÇ È£¸£¸ó ±æÇ×Á¦ | Other and unspecified hormone antagonists causing adverse effects in therapeutic use |
|
Y43 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ÀÏÂ÷Àû Àü½ÅÁ¦Á¦ | Primarily systemic agents causing adverse effects in therapeutic use |
|
Y430 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Ç׾˷¹¸£±â ¹× Ç×±¸ÅäÁ¦ | Antiallergic and antiemetic drugs causing adverse effects in therapeutic use |
|
Y431 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Ç׾ϼº ´ë»ç¾ïÁ¦Á¦ | Antineoplastic antimetabolites causing adverse effects in therapeutic use |
|
Y431 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â »çÀÌŸ¶óºó | Cytarabine causing adverse effects in therapeutic use |
|
Y432 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Ç׾ϼº õ¿¬¹° | Antineoplastic natural products causing adverse effects in therapeutic use |
|
Y433 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±âŸ Ç×¾ÏÁ¦ | Other antineoplastic drugs causing adverse effects in therapeutic use |
|